Vaccine Recommendations
Routine annual influenza vaccination is recommended for all persons aged ≥6 months. Immunization providers should consult Food and Drug Administration-approved prescribing information for 2013-14 influenza vaccines and the 2013-14 ACIP influenza recommendation statement for the most current information concerning indications, contraindications, and precautions. 
Available Influenza Vaccines for 2013-14

Note on Influenza Vaccine Abbreviations
Certain U.S. vaccine abbreviations have been revised by ACIP to refer to currently available influenza vaccines.* The revisions are as follows:
• The abbreviation TIV (trivalent influenza vaccine, previously used for inactivated influenza vaccines) has been replaced with the abbreviation IIV (inactivated influenza vaccine). For 2013-14, IIVs as a class will include 1) egg-based and cell culturebased trivalent inactivated influenza vaccine (IIV3), and 2) eggbased quadrivalent inactivated influenza vaccine (IIV4).
• RIV refers to recombinant hemagglutinin influenza vaccine, which will be available as a trivalent formulation (RIV3) for 2013-14.
• LAIV refers to live, attenuated influenza vaccine, which will be available as a quadrivalent formulation (LAIV4) for 2013-14.
• LAIV, IIV, and RIV denote vaccine categories; a numeric suffix specifies the number of influenza virus antigens contained in the vaccine.
• Where necessary to refer specifically to cell culturebased vaccine, the prefix "cc" is used (e.g., "ccIIV3"). 
